2024-513648-27-00招募中2 期
SCLERITA - Safety and efficacy of itacitinib in adults with systemic sclerosis: a phase II, randomized, controlled trial
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 74
- 试验地点
- 33
- 主要终点
- The primary outcome is the change in modified Rodnan skin score at 360 days
研究概览
简要总结
The main objective of this study is to show a decrease of skin fibrosis, as evaluated by the modified Rodnan skin score, after 360 days of treatment, in patients with diffuse SSc treated with itacitinib when compared to patients treated with a placebo
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 是
入选标准
- •Adult patient (>/= 18 years old), - Patient with a diagnosis of SSc, as defined by the American College of Rheumatology / EULAR 2013 criteria, - Patient with a diagnosis of diffuse SSc, according to LeRoy and Medgser classification - Patient with a SSc disease duration of less than 36 months (defined as time from first non-Raynaud phenomenon manifestation) or with an active SSc disease, as defined by EUSTAR disease activity score, - Patient with a modified Rodnan skin score (mRSS) > /= 10 and < /= 35 units at screening, - Negative pregnancy test for woman of childbearing potential, woman of childbearing potential should have reliable contraception for the 12 months’ duration of the study, - Patient able to give written informed consent prior to participation in the study, - Affiliation to a social security scheme (profit or being entitled). -If patients receive mycophenolate or methotrexate for SSc, these need to be on stable dose as follows: Mycophenolate mofetil/sodium: stable dose for at least 2 months prior to randomisation Methotrexate: stable dose and route of administration for at least 2 months prior to randomisation
排除标准
- •Previous treatment with itacitinib or a Janus kinase (JAK) inhibitor, - Contra-indications to itacitinib or Janus kinase inhibitor, - Failure to sign the informed consent or unable to consent - Patient participating in another investigational therapeutic study, - Acute or chronic active infections, including HBV, HCV, HIV, - Patient with other uncontrolled diseases, including drug or alcohol abuse, severe psychiatric diseases, that could interfere with participation in the trial according to the protocol, - Patient suspected not to be observant to the proposed treatments, - Patient who have white blood cell count ≤ 4,000/mm3, - Patient who have platelet count ≤ 100,000/mm3, - Patients who have ALT or AST level greater that 3 times the upper limit of normal, - Patient who have triglyceride level greater than 5g/L - Pregnant or breastfeeding woman, - Protected adults (including individual under guardianship by court order), - Patient receiving or having received cyclophosphamide or rituximab within the last three months (possible inclusion beyond 3 months), - Patient receiving or having received a biotherapy (anti-TNF, abatacept or tocilizumab) in the last 3 months (possible inclusion beyond 3 months). - Patient with Systemic Lupus, or Sjögren’s syndrome with systemic manifestations justifying immunosuppressive therapy - Atherosclerotic cardiovascular disease as defined by a history of myocardial infarction, ischaemic stroke, or peripheral artery thrombosis - Anti-phospholipid syndrome
结局指标
主要结局
The primary outcome is the change in modified Rodnan skin score at 360 days
The primary outcome is the change in modified Rodnan skin score at 360 days
次要结局
- Security profile; SSc disease activity; Quality of life and disability
研究者
Dr Benjamin CHAIGNE
Scientific
Assistance Publique Hopitaux De Paris
研究点 (33)
Loading locations...
相似试验
招募中
1 期
SCLERITA - Safety and efficacy of itacitinib in adults with systemic sclerosis: a phase II, randomized, controlled trialPatients with newly or active diffuse Systemic sclerosis (SSc) at the time of screeningMedDRA version: 21.0Level: LLTClassification code: 10042953Term: Systemic sclerosis Class: 10028395CTIS2024-513648-27-00Assistance Publique Hopitaux De Paris74
招募中
2 期
Safety and Efficacy of Itacitinib in Adults With Systemic SclerosisSystemic SclerosisNCT04789850Assistance Publique - Hôpitaux de Paris74
尚未招募
不适用
A new drug for hair loss-TofacitinibCTRI/2022/09/045386Department of Dermatology venereology and leprosy Burdwan medical college and hospital
进行中（未招募）
1 期
Efficacy of adjuvant Imatinib in patients with intermediate-risk gastrointestinal stromal tumor with a high-risk Genomic Grade Index. Multicenter, prospective, randomized study.Patients with intermediate-risk gastrointestinal stromal tumor presenting a high Genomic Grade IndexEUCTR2014-005255-87-FRAssistance Publique Hôpitaux de MARSEILLE80
进行中（未招募）
1 期
Efficacy of adjuvant Imatinib in patients with intermediate-risk gastrointestinal stromal tumor with a high-risk Genomic Grade Indexgastrointestinal stromal tumorCTIS2024-515432-71-00Centre Hospitalier Regional De Marseille80